Skip to main content

Report

New drugs for Alzheimer's, multiple sclerosis and more

First self-administered Alzheimer's therapy shifts costs to pharmacy plans, plus first treatments for MS and bronchiectasis.

Spread of the report with an illustration of an IV bag, prescription bottle, syringe and pills. Spread of the report with an illustration of an IV bag, prescription bottle, syringe and pills.

Welcome to the Summer 2025 Notable New Drugs™ Report

In this latest edition, we highlight key new drugs that are expected to receive U.S. Food and Drug Administration (FDA) approval before the end of September 2025. This includes:

  • Brensocatib to treat patients with non-cystic fibrosis bronchiectasis. 
  • Tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis (MS). 
  • Leqembi® SC (lecanemab) a new, subcutaneous form of the existing intravenous Leqembi to treat Alzheimer's disease.

As always, our Optum Rx pipeline surveillance team continuously monitors and evaluates the drug development pipeline to share important upcoming drug approvals. Please refer here for additional technical background and supplemental sources.

Download report

Don't want to read the full report?

View summary

Related healthcare insights

View all

Report

Better drugs? Maybe. Higher cost? Definitely.

New drugs for myasthenia gravis and hereditary angioedema will be easier to take, more effective, and add competition.

Report

New treatments for rare and common conditions

Our report emphasizes new, next-gen and first-in-class treatments for cystic fibrosis, non-opioid treatment and GLP-1 drugs.

Article

Key new drugs help close out 2024

New biologics for breast cancer, hemophilia, and a rare form of heart disease are poised to add competition and choice in these classes.